Literature DB >> 16280341

Metabolic syndrome and cardiovascular disease.

Leslie Citrome1.   

Abstract

Metabolic syndrome is a constellation of clinical findings that identify individuals at higher than normal risk of developing diabetes mellitus or cardiovascular disease. There are two principal definitions, one emerging from the American National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, and the other from the World Health Organization. Both definitions share the common elements of abdominal obesity, hypertriglyceridaemia, low HDL-cholesterol, hypertension and abnormal glucose regulation. The syndrome is relatively common across continents, and also among those without marked obesity. It is even more common among patients with major mental health disorders such as schizophrenia. Metabolic syndrome can be used to assess risk for cardiovascular disorder and death, and is an alternative to Framingham Risk Calculations. C-reactive protein may play an additional role in risk prediction. Ongoing monitoring for all components of the metabolic syndrome is necessary. Individuals at high risk require multimodal interventions, including lifestyle interventions and targeted medications as appropriate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280341     DOI: 10.1177/0269881105058375

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  6 in total

Review 1.  Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Authors:  Leslie Citrome; Richard I G Holt; Daniel J Walker; Vicki Poole Hoffmann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

3.  Prevalence of metabolic syndrome among patients with schizophrenia in Palestine.

Authors:  Waleed M Sweileh; Sa'ed H Zyoud; Salah A Dalal; Sami Ibwini; Ansam F Sawalha; Iyad Ali
Journal:  BMC Psychiatry       Date:  2012-12-27       Impact factor: 3.630

4.  Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics.

Authors:  Shiv Gautam; Parth Singh Meena
Journal:  Indian J Psychiatry       Date:  2011-04       Impact factor: 1.759

5.  Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome.

Authors:  Zohreh Mousavi; Azita Ganji; Donya Farrokh Tehrani; Ali Bahari; Abbas EsmaeilZadeh; Mehdi Delghandi
Journal:  Med J Islam Repub Iran       Date:  2017-05-28

6.  Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia.

Authors:  Feyissa Challa; Tigist Getahun; Meron Sileshi; Zeleke Geto; Teshome S Kelkile; Sintayehu Gurmessa; Girmay Medhin; Miraf Mesfin; Melkam Alemayehu; Tigist Shumet; Anwar Mulugeta; Desalegn Bekele; Christina P C Borba; Claire E Oppenheim; David C Henderson; Abebaw Fekadu; Anna Carobene; Solomon Teferra
Journal:  BMC Psychiatry       Date:  2021-12-11       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.